If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    The tenth anniversary of RDD Europe: A great success for the international Respiratory Drug Delivery community

    Quick Contact
    The tenth anniversary of RDD Europe: A great success for the international Respiratory Drug Delivery community
    Health

    RDD® Europe 2015 hosted 450 pulmonary and nasal drug delivery experts from 31 countries at its latest conference in Antibes, France, demonstrating once again that it is the "must attend" European event in pulmonary and nasal drug delivery.

    From May 5 to 8, RDD Europe 2015, recognized internationally by experts for the quality of its programme, attracted delegates from Europe (61%), North America (23%) and the rest of the world's aerosol community (16%).

    RDD Europe is a prestigious event, bringing together scientists, clinicians, business professionals and regulators to further research, development, clinical evaluation and marketing of current and new drugs delivered through the lungs or nose. Its focus is development of innovative products and services to meet patient needs.

    RDD Europe 2015 hosted 22 speakers, 65 scientific poster presenters, 60 exhibitors and 12 interactive workshops.
    Topics included:

    • Back to Biotech-Personalised Medicine and New Drug Development
    • Global Patent Practice
    • Nasal Drug Delivery
    • Pulmonary and Nasal Delivery: Exploring Alternative Technologies
    • Particle Engineering and Quality by Design
    • Alternative Distribution Practices for Inhalers

    RDD Online and Aptar Pharma, the joint organizers of this scientific conference are extremely pleased that the
    audience found this year's European meeting to be of outstanding quality with a record number of scientific posters.
    Many report it is the most important international event they attend in terms of both science and networking.

    Tenth anniversary celebration

    RDD Europe celebrated its 10th anniversary in Antibes, although the parent US conference began in 1988. Aptar Pharma has been part of RDD meetings from the outset, but in 2005 partnered with RDD to formally lend its expertise in nasal and pulmonary drug administration and to increase the accessibility of the meeting to international delegates.

    In Antibes, Aptar Pharma sponsored the gala dinner, providing attendees with an additional opportunity to network and exchange views and information with their peers in a friendly and convivial atmosphere - another facet of this three-day conference that sets RDD Europe apart from other events.

    Aptar Pharma has released a videoclip which underlines some highlights of RDD Europe 2015.

    "Aptar Pharma is particularly proud of supporting, and being affiliated with, this major conference. The successful outcome of this tenth anniversary of RDD Europe and feedback from the delegates are a source of great satisfaction for all those involved", stated Pierre Carlotti, Vice President Marketing and Communication at Aptar Pharma, Prescription, and Conference Coordinator at RDD Europe.

    "The quality of the contributions this year was outstanding, reflecting major advances in our industry and the importance of this conference, which brings together key players in the respiratory drug delivery sector", added Dr. Richard Dalby, one of the organizers from the University of Maryland.


    Imagery courtesy of Aptar Pharma.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 27 Jan 2022
    • Hits 2218
    SR Packaging
    Webpackaging
    Conzept International